Chart, Financials, Historical Prices, Industry, Insider, Messages, Profile, Reports, Research, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 24-Nov-2009
New Screen 

All Reports | Brokerage Reports | Independent Reports
All Reports (Showing 1 to 10 of 34)
Release
Date
 [down]
Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
24-Nov-09ValuEngine, Inc.N/AValuEngine Industry Report for HOME HEALTH CARE18$49  View Abstract
23-Nov-09ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for TRIB13$25  View Abstract
23-Nov-09Market EdgeN/AMarket Edge Equity Research Report4$10  View Abstract
22-Nov-09TheStreet.com RatingsN/ATheStreet.com Ratings Stock Report For: TRINITY BIOTECH PLC5$25  View Abstract
21-Nov-09Standard & Poor's Quantitative ReportN/ATrinity Biotech plc ADR5$25  View Abstract
21-Nov-09Pechala's ReportsLubomir PechalaTRINITY BIOTECH PLC (TRIB=US) 2-weeks forecast1$10  View Abstract
21-Nov-09Pechala's ReportsFrantisek PechalaTRINITY BIOTECH PLC (TRIB=US) 12-months forecast1$15  View Abstract
17-Nov-09Zacks Investment Research Inc.N/ATRINITY BIOTECH (TRIB) Zacks Company Snapshot1$10  View Abstract
17-Nov-09EconomicInvestorN/A"The Economy Matters" Report for TRIB: the economy's impact on TRIB's price and risk, featuring the powerful EconomicInvestor Star Rating6$15  View Abstract
16-Nov-09PriceTarget Research, Inc.N/ATrinity Biotech PLC has a current Overall Rating of A (Highest Rating).7$25  View Abstract
Next 20

Brokerage Reports (Showing 1 to 10 of 10)
Release
Date
 [down]
Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
22-Oct-09Roth Capital Partners, Inc.Research DepartmentMorning Call Summary18$50  View Abstract
22-Oct-09Thomson StreetEventsN/ATRIB - Event Transcript of Trinity Biotech conference call, Oct. 21, 2009 / 4:00pm ET18$75  View Abstract
21-Oct-09Roth Capital Partners, Inc.Matt DolanEPS Beat Shows Continued Efficiencies; HIV Should Recover; Maintain Buy7$254 Stars  View Abstract
21-Oct-09Roth Capital Partners, Inc.Research DepartmentMorning Call Summary18$50  View Abstract
20-Oct-09Roth Capital Partners, Inc.Matt DolanTrinity Biotech (TRIB) 3Q09 Earnings Preview3$104 Stars  View Abstract
20-Oct-09Roth Capital Partners, Inc.Research DepartmentMorning Call Summary13$50  View Abstract
15-Oct-09Roth Capital Partners, Inc.Research DepartmentMorning Call Summary14$50  View Abstract
14-Oct-09Roth Capital Partners, Inc.Matt Dolan3Q09 Medical Device Earnings Preview: Part 16$254 Stars  View Abstract
12-Oct-09Roth Capital Partners, Inc.Research DepartmentMorning Call Summary13$50  View Abstract
9-Oct-09Roth Capital Partners, Inc.Matt Dolan3Q 2009: Quarterly Medical Device Trading & Acquisition Valuation Update8$254 Stars  View Abstract

Independent Reports (Showing 1 to 10 of 24)
Release
Date
 [down]
Contributor Author Title Pages Price More Info
24-Nov-09ValuEngine, Inc.N/AValuEngine Industry Report for HOME HEALTH CARE18$49View Abstract
23-Nov-09ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for TRIB13$25View Abstract
23-Nov-09Market EdgeN/AMarket Edge Equity Research Report4$10View Abstract
22-Nov-09TheStreet.com RatingsN/ATheStreet.com Ratings Stock Report For: TRINITY BIOTECH PLC5$25View Abstract
21-Nov-09Standard & Poor's Quantitative ReportN/ATrinity Biotech plc ADR5$25View Abstract
21-Nov-09Pechala's ReportsLubomir PechalaTRINITY BIOTECH PLC (TRIB=US) 2-weeks forecast1$10View Abstract
21-Nov-09Pechala's ReportsFrantisek PechalaTRINITY BIOTECH PLC (TRIB=US) 12-months forecast1$15View Abstract
17-Nov-09Zacks Investment Research Inc.N/ATRINITY BIOTECH (TRIB) Zacks Company Snapshot1$10View Abstract
17-Nov-09EconomicInvestorN/A"The Economy Matters" Report for TRIB: the economy's impact on TRIB's price and risk, featuring the powerful EconomicInvestor Star Rating6$15View Abstract
16-Nov-09PriceTarget Research, Inc.N/ATrinity Biotech PLC has a current Overall Rating of A (Highest Rating).7$25View Abstract
Next 14

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.


Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.